Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8238415 | 1.00 | RBP4 (0.42) | RBP4CNR2PIK3CDALDH1A1TSHR | |
| SCHEMBL9706890 | 1.00 | RBP4 (0.42) | RBP4CNR2PIK3CDALDH1A1TSHR | |
| SCHEMBL8232622 | 0.86 | PARP1 (0.42) | RBP4PIK3CDALDH1A1TSHRRECQL | |
| SCHEMBL7558692 | 0.86 | PARP1 (0.42) | RBP4PIK3CDALDH1A1TSHRRECQL | |
| SCHEMBL7558696 | 0.86 | PARP1 (0.42) | RBP4PIK3CDALDH1A1TSHRRECQL | |
| SCHEMBL1704378 | 0.86 | CNR2 (0.36) | CNR2ALDH1A1 | |
| SCHEMBL3054057 | 0.86 | CNR2 (0.36) | CNR2ALDH1A1 | |
| SCHEMBL584199 | 0.79 | CNR2 (0.37) | CNR2POLB | |
| SCHEMBL10735686 | 0.71 | CNR2 (0.35) | CNR2 | |
| SCHEMBL4161364 | 0.71 | CHRM2 (0.38) | CNR2SMN1; SMN2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0748247-B1 | Macrocyclic antibiotics as separation agents | UNIV MISSOURI (US) | 2012-06-20 | — | — | EP | disclosed |
| US-6596898-B2 | Making a 2-fluoro-2-chlorocyclopropanecarboxylic acid derivative stereoselectively in high yield by reacting a diazoacetic acid derivative with 1-fluoro-1-chloroethylene using metal catalyst having chiral ligands | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20010051750-A1 | PROCESS FOR PREPARING HALOGENATED CYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-0858992-B1 | PROCESS FOR PRODUCING HALOGENATED CYCLOPROPANE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2001-12-12 | — | — | EP | disclosed |
| EP-0858992-A1 | PROCESS FOR PRODUCING HALOGENATED CYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
| EP-0624163-B1 | CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION | SMITHKLINE BEECHAM FARMA (IT) | 1998-03-25 | — | — | EP | disclosed |
| EP-0624163-A1 | CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1994-11-17 | — | — | EP | disclosed |
| WO-1993015106-A1 | CYCLIC CALCITONINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1993-08-05 | — | — | WO | disclosed |
| EP-0237630-A2 | Process for the preparation of chiral glycine derivatives | Degussa Aktiengesellschaft (DE) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051750-A1 | PROCESS FOR PREPARING HALOGENATED CYCLOPROPANE DERIVATIVES | CYP2F1, CYP4F2, CYP4F8 | RBP4 3264/4885CNR2 134/4885PIK3CD 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.